Is this true ????
Headline FDA delivers crushing blows to abuse-deterrent opioids (Subscription Only)
Source EP Vantage
Company Pfizer, Acura Pharmaceuticals, DURECT, Endo Health Solutions, Pain Therapeutics, Purdue Pharma
Date May 13, 2013
Pain Therapeutics investors are right to be cautious at the fact that Pfizer is considering handing back rights to Pain’s oxycodone formulation Remoxy. The FDA's demand for more data had set the filing date back to mid-2015, and while Pfizer has not yet made a definite decision the market was spooked badly, halving Pain’s share price to $2.68.
Last month, the FDA updated the label for Purdue Pharma’s controlled-release form of OxyContin – the only branded version currently sold – to state that it is better at deterring abuse than other formulations. But last week, the agency rejected Endo Endo Health Solutions’ claim that another putatively tamper-resistant opioid, Opana ER, was better at deterring abuse than generic versions of oxymorphone. It is possible that no other product will ever be able to match OxyContin’s abuse-resistant designation.
(Subscription Only Story)
Market Data 
Markets 
AI
